Aldeyra Therapeutics Files 8-K
Ticker: ALDX · Form: 8-K · Filed: Aug 19, 2025 · CIK: 1341235
| Field | Detail |
|---|---|
| Company | Aldeyra Therapeutics, INC. (ALDX) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
Related Tickers: ALDX
TL;DR
Aldeyra Therapeutics (ALDX) filed an 8-K on 8/19/25 for financial statements & exhibits.
AI Summary
Aldeyra Therapeutics, Inc. filed an 8-K on August 19, 2025, reporting financial statements and exhibits. The company, incorporated in Delaware, is headquartered in Lexington, MA, and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates Aldeyra Therapeutics is providing updated financial statements and exhibits, which are crucial for investors to assess the company's financial health and operational status.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate material adverse events.
Key Numbers
- 001-36332 — Commission File Number (Identifies the company's filing with the SEC.)
- 20-1968197 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- August 19, 2025 (date) — Date of earliest event reported
- Lexington, MA (location) — Principal executive offices
- 001-36332 (other) — Commission File Number
- 20-1968197 (other) — IRS Employer Identification No.
FAQ
What specific financial statements or exhibits are being filed?
The filing states 'Financial Statements and Exhibits' as the item information, but the specific details of these documents are not provided in this summary.
Has Aldeyra Therapeutics changed its name recently?
The filing mentions former names 'Aldexa Therapeutics, Inc.' (changed Jan 2, 2013) and 'Neuron Systems Inc' (changed Oct 12, 2005), indicating past name changes.
What is Aldeyra Therapeutics' primary business sector?
Aldeyra Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are Aldeyra Therapeutics' principal executive offices located?
The principal executive offices are located at 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
What is the significance of filing an 8-K on this date?
Filing an 8-K on August 19, 2025, signifies that Aldeyra Therapeutics is reporting a material event or information, in this case, related to financial statements and exhibits.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 9.2 · Accepted 2025-08-19 07:00:27
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
Filing Documents
- aldx-20250819.htm (8-K) — 58KB
- aldx-ex99_1.htm (EX-99.1) — 26KB
- img112526854_0.jpg (GRAPHIC) — 49KB
- 0000950170-25-109932.txt ( ) — 269KB
- aldx-20250819.xsd (EX-101.SCH) — 30KB
- aldx-20250819_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On August 19, 2025, Aldeyra Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") to announce that the U.S. Food and Drug Administration has granted Fast Track Designation for ADX-2191 for the treatment of retinitis pigmentosa. The Press Release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Aldeyra Therapeutics, Inc. Press Release dated August 19, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady M.D., Ph.D. Title: Chief Executive Officer Dated August 19, 2025